Novartis halts CAR-T trials after three patient deaths from an immune overreaction; Bristol Myers pauses zola-cel enrollment.
ARCH Venture Partners is targeting $3B for its 14th fund, per an SEC filing, matching the size of the fund it disclosed in ...
Nine more drugmakers strike voluntary drug-pricing deals with the White House, pledging nearly $20B in US investments to avoid tariffs and CMS pricing pilots.
Sanofi-backed Electra files for a Nasdaq IPO to fund Phase 2/3 trials of ipsoprubart, its lead antibody for the rare disease ...
Eli Lilly acquires Merida Biosciences for up to $2.875B, gaining MER511 for thyroid eye disease/Graves' disease and MER769 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results